Net income
-205 million USD
2025-07-01 – 2026-06-30
Fundies. English
Olema Pharmaceuticals, Inc.
EDGAR32 filing records in this dataset, filed from 2020-10-13 to 2026-10-15. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 48.6 million USD Source
Exact value
48599000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 87.5 million shares Source
Exact value
87452166 shares
Reported share-count change
27.43% · 18.8 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-165 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -108389000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -73862000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -146716000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -108389000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -45987000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -91883000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -45987000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-15.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 4 of 11 periods available· newest 2025-12-31
- Net income: 4 of 11 periods available· newest 2025-12-31
- Operating cash flow: 4 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2024-12-31
- Total assets: 4 of 11 periods available· newest 2025-12-31
- Total liabilities: 4 of 11 periods available· newest 2025-12-31
- Current assets: 4 of 11 periods available· newest 2025-12-31
- Current liabilities: 4 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 4 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 32.98 millionPrior period
−USD 129.47 million
–
Current period
−USD 162.45 million
–
Exact inputs and evidence
-162451000 − -129474000 = -32977000 USD
-129474000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-162451000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 42.37 millionPrior period
−USD 104.35 million
–
Current period
−USD 146.72 million
–
Exact inputs and evidence
-146716000 − -104351000 = -42365000 USD
-104351000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-146716000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | −USD 104.79 million Exact valueExact value: -104787000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 82.07 million Exact valueExact value: -82065000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 363,000 Exact valueExact value: 363000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 82.43 million Calculation and evidence-82065000 − 363000 USD Exact free cash flow: -82428000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 96.66 million Exact valueExact value: -96655000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 83.73 million Exact valueExact value: -83727000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 129.47 million Exact valueExact value: -129474000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 104.35 million Exact valueExact value: -104351000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 159,000 Exact valueExact value: 159000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 104.51 million Calculation and evidence-104351000 − 159000 USD Exact free cash flow: -104510000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 162.45 million Exact valueExact value: -162451000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 146.72 million Exact valueExact value: -146716000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
32 filings · 1,987 latest values · 1,987 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001750284, 1750284, OLMA, edgar:1750284
Also known as OLEMA PHARMACEUTICALS, INC., OLEMA PHARMACEUTICALS, INC., Olema Pharmaceuticals, Inc.